ES2117035T3 - Derivados antiproliferativos del 4-h-nafto(1,2-b)pirano. - Google Patents

Derivados antiproliferativos del 4-h-nafto(1,2-b)pirano.

Info

Publication number
ES2117035T3
ES2117035T3 ES92309169T ES92309169T ES2117035T3 ES 2117035 T3 ES2117035 T3 ES 2117035T3 ES 92309169 T ES92309169 T ES 92309169T ES 92309169 T ES92309169 T ES 92309169T ES 2117035 T3 ES2117035 T3 ES 2117035T3
Authority
ES
Spain
Prior art keywords
alkyl
carboxide
hydrogen
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309169T
Other languages
English (en)
Inventor
Colin Peter Dell
Colin William Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Application granted granted Critical
Publication of ES2117035T3 publication Critical patent/ES2117035T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTA UN COMPUESTO FARMACEUTICO DE LA FORMULA (I) EN LA CUAL N ES 0,1 O 2 Y R1 ESTA SUJETA A CUALQUIERA DE LAS POSICIONES 5, 6, 7, 8, 9 O 10, Y CADA R1 ES HALO, TRIFLUOROMETIL, ALCOXIDO C1-C4, HIDROXIDO, NITRO, ALQUIL C1-C4, ALQUILTIO C1-C4, HIDROXIALQUIL C1-C4, HIDROXIALCOXIDO C1-C4, TRIFLUOROMETIL, CARBOXIDO, -COOR5 EN DONDE R5 ES UN GRUPO ESTER, -CONR6R7 O NR6R7 DONDE R6V Y R7 SON CADA HIDROGENO O ALQUIL C1-C4; E2 ES FENIL, NAFTIL O HETEROARIL SELECCIONADO ENTRE TIENIL, PIRIDIL, BENZOTIENIL, QUINOLINIL, BENZOFURANGIL O BENZIMIDAZOLIL, DICHOS GRUPOS DE FENIL, NAFTIL Y HETEROARIL ESTAN OPCIONALMENTE SUBSTITUIDOS, O R2 ES FURANIL OPCIONALMENTE SUBSTITUIDO CON ALQUIL C1-C4; R3 ES NITRILO, CARBOXIDO, -COOR8 DONDE R8 ES UN GRUPO ESTER, -CONR9R10 DONDE R9 Y R10 SON CADA UNA HIDROGENO O ALQUIL C1-C4, O R11SO2TE SUBSTITUIDO; Y R4 ES -NR12R13, -NHCOR12, -N(COR12)2 O -N=CHOCH2R12 DONDE R12 Y R13 SON CADA UNA HIDROGENO O ALQUIL C1-C4 OPCIONALMENTE SUBSTITUIDO CON CARBOXIDO, O LA SIGUIENTE FORMULA EN DONDE X ES ALQUILENO C2-C4 O -NHSO2R14 DONDE R14 ES ALQUIL C1C4 O FENIL OPCIONALMENTE SUBSTITUIDO; CON LA CONDICION DE QUE CUANDO N ES 0, R3 ES NITRILO Y R4 ES -NH, R2 NO ES FENIL O FENIL SUBSTITUIDO EN LA POSICION PARA CON UN SUBSTITUYENTE SIMPLE DE CLORO, HIDROXIDO O METOXIDO. ASIMISMO SE PRESENTAN LAS SALES DE LOS COMPUESTOS.
ES92309169T 1991-10-09 1992-10-08 Derivados antiproliferativos del 4-h-nafto(1,2-b)pirano. Expired - Lifetime ES2117035T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2117035T3 true ES2117035T3 (es) 1998-08-01

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309169T Expired - Lifetime ES2117035T3 (es) 1991-10-09 1992-10-08 Derivados antiproliferativos del 4-h-nafto(1,2-b)pirano.

Country Status (22)

Country Link
US (1) US5284868A (es)
EP (1) EP0537949B1 (es)
JP (1) JPH05194477A (es)
KR (1) KR100228841B1 (es)
CN (1) CN1034938C (es)
AT (1) ATE167859T1 (es)
AU (1) AU658003B2 (es)
CA (1) CA2079428A1 (es)
CZ (1) CZ281688B6 (es)
DE (1) DE69226060T2 (es)
DK (1) DK0537949T3 (es)
ES (1) ES2117035T3 (es)
FI (1) FI924551A (es)
HU (1) HU218916B (es)
IL (1) IL103356A (es)
MX (1) MX9205714A (es)
MY (1) MY111368A (es)
NO (1) NO301587B1 (es)
NZ (1) NZ244627A (es)
PH (1) PH30659A (es)
RU (1) RU2071472C1 (es)
TW (1) TW221292B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP1004584A3 (en) * 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
PT1230232E (pt) 1999-11-05 2004-07-30 Cytovia Inc 4h-cromeno substituido e seus analogos como activadores de caspases e indutores de apoptose e sua utilizacao
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1392283A4 (en) * 2001-05-16 2004-10-20 Cytovia Inc COUMARINS AND SUBSTITUTED QUINOLINES USED AS CASPASE ACTIVATORS
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
AU2003241482A1 (en) * 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1509515A4 (en) * 2002-05-16 2006-07-05 Cytovia Inc SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
WO2006026832A1 (en) * 2004-09-09 2006-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Enzyme inhibitors and uses thereof
US20080146655A1 (en) * 2005-02-16 2008-06-19 Md Bioalpha Co., Ltd. Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
CN107235954A (zh) 2010-11-12 2017-10-10 德国癌症研究中心 作为Wnt通路拮抗剂的色烯衍生物及其类似物
US20140275174A1 (en) 2011-11-10 2014-09-18 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (ru) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Способ получени 2-ароил-3н- нафто 2,1-в пиранонов-3
US5232942A (en) * 1988-04-14 1993-08-03 Yamanouchi Pharmaceutical Co., Ltd. Q-2819 substance and the use thereof

Also Published As

Publication number Publication date
FI924551A0 (fi) 1992-10-08
US5284868A (en) 1994-02-08
JPH05194477A (ja) 1993-08-03
HU9203183D0 (en) 1992-12-28
PH30659A (en) 1997-09-16
MX9205714A (es) 1993-04-01
ATE167859T1 (de) 1998-07-15
CZ281688B6 (cs) 1996-12-11
HUT62281A (en) 1993-04-28
CN1073437A (zh) 1993-06-23
KR100228841B1 (ko) 1999-11-01
NO923910D0 (no) 1992-10-08
DK0537949T3 (da) 1999-02-15
CZ303592A3 (en) 1993-12-15
AU2621692A (en) 1993-04-22
CN1034938C (zh) 1997-05-21
FI924551A (fi) 1993-04-10
AU658003B2 (en) 1995-03-30
NO923910L (no) 1993-04-13
MY111368A (en) 1999-12-31
HU218916B (hu) 2000-12-28
CA2079428A1 (en) 1993-04-10
NZ244627A (en) 1994-12-22
IL103356A (en) 1998-02-22
DE69226060D1 (de) 1998-08-06
NO301587B1 (no) 1997-11-17
EP0537949A1 (en) 1993-04-21
TW221292B (es) 1994-02-21
IL103356A0 (en) 1993-03-15
RU2071472C1 (ru) 1997-01-10
KR930007931A (ko) 1993-05-20
DE69226060T2 (de) 1998-11-19
EP0537949B1 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
ES2117035T3 (es) Derivados antiproliferativos del 4-h-nafto(1,2-b)pirano.
PA8450401A1 (es) Pirazolopirimidonas para la disfuncion sexual
CO5640136A2 (es) Derivados de hexahidropiridoisoquinolinas inhibidores de dpp-iv y composiciones farmaceuticas que los contienen
ES2163004T3 (es) Feniloxazolidinona sustituida por un anillo heteroaromatico como agente antimicrobiano.
ES2162989T3 (es) Nuevos derivados de la piperazina, de la piperidina y de la 1,2,5,6-tetrahidro-piridina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2110421T3 (es) O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2101223T3 (es) Composicion de aciete de refrigerador para refrigerante de fluoroalcano.
MX9205817A (es) Derivados de benzodiazepina, procedimiento para supreparacion y medicamentos que los contienen
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2059804T3 (es) Procedimiento de preparacion de eteres de oxima de propenona.
ES2054940T3 (es) Agentes contra parasitos en peces que contienen derivados de triacindiona.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
AR246270A1 (es) Un procedimiento para producir derivados de tieno-¡2,3-d¿azepina.
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2057802T3 (es) Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2136614T3 (es) Derivados de 1,4-dihidropiridina, su procedimiento de preparacion y composicion terapeutica que los contiene.
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
GT199900113A (es) Inhibidores de las fkbp.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.
PA8495201A1 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano
MX9101948A (es) Composicion farmaceutica que contiene derivados de tiazoloisoindolinona
ES2123739T3 (es) Nuevos analogos del eburnano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2057901T3 (es) Derivados de benzotiazol, su preparacion y los medicamentos que les contienen.
ES2095714T3 (es) Nuevas amino-alquil-cromonas, sus procedimientos de preparacion y las composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 537949

Country of ref document: ES